Medical Communications

Showing 15 posts of 6414 posts found.

FDA approves first new fibromyalgia therapy in over 15 years

August 18, 2025 Medical Communications, Research and Development Pain, Tonix Pharmaceutical, US Food and Drug Administration, chronic pain, clinical trial, fibromyalgia

The US Food and Drug Administration (FDA) has approved Tonix Pharmaceutical’s Tonmya (cyclobenzaprine hydrochloric acid) for the treatment of fibromyalgia …

NICE recommends Benralizumab for Rare Form of Vasculitis

August 15, 2025 Medical Communications, Research and Development AstraZeneca, Immunology, National Institute for Health and Care Excellence, vasculitis

The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as an add-on treatment for adult …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition

August 14, 2025 Medical Communications, Research and Development European Alliance of Associations for Rheumatology, European Medicines Agency, IgG4-related disease, Rheumatology, Sanofi

The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) inhibitor, rilzabrutinib, for the treatment …

Eyestem secures $10m to advance cell therapy for advanced eye disease

August 13, 2025 Medical Communications, Research and Development Eyestem, Opthalmology, cell therapy, dry age-related macular degeneration, geographic atrophy

Indian cell therapy company, Eyestem Research, has raised $10m in a funding round to support development of its investigational retinal …

NICE recommends treatment for rare genetic eye disorder

August 11, 2025 Medical Communications Chiesi, Leber Hereditary Optic Neuropathy, NHS England, National Institute for Health and Care Excellence, Opthalmology, Rare Diseases

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Cheisi’s idebenone (Raxone) within its …

ARTBIO expands board and establishes technical advisory board

August 11, 2025 Medical Communications, Research and Development ARTBIO, Corporate, Oncology, advisory board, radiopharmaceuticals

ARTBIO, a radiopharma company developing radioligand therapies (RLTs), has appointed four new members to its board of directors and formed …

Lilly reports positive results from trial of obesity candidate

August 8, 2025 Medical Communications, Research and Development Eli Lilly and Company, Obesity, cardiovascular risk, high blood pressure, obesity

Eli Lilly and Company (Lilly) has announced topline results from its phase 3 ATTAIN-1 trial, showing that orforglipron – a …

Rollout of world-first gonorrhoea vaccine programme begins under NHS

August 8, 2025 Medical Communications 10 Year Health Plan, Genito-Urinary system, Infections and infestations, NHS, gonorrhoea, sexual health, sexually transmitted infections, vaccination

From 4 August, sexual health clinics in England have been able to offer a free vaccine – the 4CMenB vaccine …

Faron reports increased remission rate in trial for myelodysplastic syndrome candidate

August 7, 2025 Medical Communications, Research and Development Faron Pharmaceuticals, Oncology, US Food and Drug Administration, acute myeloid leukemia, myelodysplastic syndrome

Faron Pharmaceuticals has reported a rise in complete remission (CR) rates among patients with frontline high-risk myelodysplastic syndrome (HR-MDS) in …

PLL Therapeutics to present ALS research strategy at Bioshares Biotech Summit

August 7, 2025 Medical Communications, Research and Development Bioshares Biotech Summit, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis, neurodegenerative diseases

French biotech, PLL Therapeutics, will present its approach to early detection and treatment of Amyotrophic Lateral Sclerosis (ALS) at the …

Lilly’s drug for early Alzheimer’s shows promising results

August 6, 2025 Medical Communications, Research and Development Alzheimer's, Eli Lilly, Neurology, dementia

Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase 3 study, showing that Kisunla …

FDA grants orphan drug designation to relapsed or refractory multiple myeloma candidate

August 6, 2025 Medical Communications, Research and Development Oncology, Sanofi, US Food and Drug Administration, myeloma

The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, Sanofi’s investigational monoclonal antibody developed for …

Five Facts about sleep and mental health

August 3, 2025 Medical Communications Five Facts, Psychiatry, insomnia, mental health, sleep, sleep disorders, sleep health

1 Rapid Eye Movement (REM) sleep enhances creative thinking and helps the brain form connections between ideas, supporting mental wellbeing …

Ryvu Therapeutics publishes research revealing potential drug combination for colorectal cancer

August 1, 2025 Medical Communications, Research and Development Oncology, Ryvu Therapeutics, colorectal cancer

Ryvu Therapeutics has published new findings from its ONCO Prime target discovery platform in Scientific Reports. The study reveals a …
The Gateway to Local Adoption Series

Latest content